Related Experiment Video
Updated: Jun 6, 2025

Reduced Itraconazole Concentration and Durations Are Successful in Treating Batrachochytrium dendrobatidis Infection in Amphibians
Published on: March 14, 2014
Aspergillus spondylodiscitis successfully treated with a long course of isavuconazole
Francisco Javier Teigell Muñoz1, Ana Sánchez-de Torre2, Marta Jiménez-Fernández3
1Internal Medicine Department, Infanta Cristina University Hospital, Madrid, Spain.
Abstract:
We present a case of spondylodiscitis caused by Aspergillus fumigatus, which we successfully treated with isavuconazole after voriconazole severe intolerance. Aspergillus spondylodiscitis is a severe and relatively rare form of extra-pulmonary invasive aspergillosis. Typically, voriconazole is the first-choice antifungal drug for treating Aspergillus osteomyelitis or spondylodiscitis. However, isavuconazole, a new antifungal medication, has been demonstrated as non-inferior to voriconazole in cases of invasive aspergillosis. It has the added benefits of fewer hepatobiliary, ocular, and cutaneous side effects. It generally does not demand serum level monitoring and poses fewer risks of drug interactions. Nonetheless, there are no studies yet that support its use in spondylodiscitis, and published experiences are very limited and based on isolated cases, albeit mainly positive. The case we present here aims to provide additional evidence on the efficacy and tolerability of isavuconazole in treating this condition.
Insights
This case study demonstrates successful treatment of Aspergillus spondylodiscitis using isavuconazole when voriconazole was not tolerated. Isavuconazole offers a promising alternative for invasive aspergillosis with fewer side effects.
Area of Science:
- Mycology
- Infectious Diseases
- Clinical Medicine
Background:
- Aspergillus spondylodiscitis is a rare, severe invasive aspergillosis form.
- Voriconazole is the standard first-line treatment for Aspergillus osteomyelitis and spondylodiscitis.
Observation:
- A patient with Aspergillus spondylodiscitis experienced severe intolerance to voriconazole.
- Isavuconazole was administered as an alternative antifungal therapy.
Findings:
- The patient was successfully treated with isavuconazole, demonstrating its efficacy.
- Isavuconazole exhibited good tolerability, with fewer adverse effects compared to voriconazole.
Implications:
- Isavuconazole presents a viable alternative for invasive aspergillosis, particularly spondylodiscitis, when voriconazole is contraindicated.
- This case contributes to the limited but growing evidence supporting isavuconazole's use in complex fungal infections.
- Further research is warranted to establish isavuconazole's role in treating Aspergillus spondylodiscitis.
Related Concept Videos
Endocarditis III: Medical Management
Drugs for Treatment of Ulcerative Colitis in IBD
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Pulmonary Tuberculosis V
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the...

